To determine whether A2AR suppresses anti-tumor immunity in the RencaHA model, we treated RencaHA tumor-bearing mice intraperitoneally with 10 mg/kg of the A2AR antagonist ZM 241385 every 4 days (Fig. 1)32,33. The gene discussed is ADORA2A; the disease is neoplasm.